Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients.
Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients.
复制标题
DOI：
10.1210/jcem.76.4.7682560
复制
发表时间：
1993-04
期刊：
影响因子：
--
通讯作者：
Pinhas Cohen;D. Peehl;T. Stamey;K. Wilson;D. Clemmons;R. Rosenfeld
中科院分区：
文献类型：
--
作者：
Pinhas Cohen;D. Peehl;T. Stamey;K. Wilson;D. Clemmons;R. Rosenfeld
我们以前已经证明存在特定的胰岛素样生长因子（IGF）结合蛋白（IGFBPs）在精浆和前列腺上皮细胞条件培养基IGFBP-2是流行的IGFBP在这两种液体。为了评估前列腺癌患者血清IGFP水平是否与肿瘤产生IGFBP相关，我们对32例不同临床严重程度的前列腺癌患者的血清样本进行了Western配体印迹（WLB）和IGFBP-2 RIA，并将其与16例健康年龄匹配的对照组进行了比较。我们还测定了血清IGF-I和IGF-II的RIA。WLB法检测前列腺癌患者血清IGFBP-2水平为正常对照组的170%，RIA法检测为正常对照组的195%（P < 0.01）。IGFBP-2升高的程度与肿瘤分期及血清肿瘤标志物前列腺特异性抗原水平有关。WLB法测定的血清IGFBP-3水平和放免法测定的血清IGF-I、IGF-II水平在癌症组和正常对照组之间无显著性差异。我们的结论是IGFBP-2，这是前列腺上皮细胞产生的主要IGFBP，是升高的前列腺癌患者的血清中，这种升高的程度与血清前列腺特异性抗原水平和肿瘤的阶段。我们推测前列腺源性IGFBPs可能是由前列腺肿瘤分泌的，并且可能对了解前列腺肿瘤生长的病理生理学以及提供潜在的诊断标记物具有价值。
We have previously documented the presence of specific insulin-like growth factor (IGF)-binding protein (IGFBPs) in seminal plasma and prostate epithelial cell-conditioned medium IGFBP-2 is the prevalent IGFBP in both fluids. To assess whether patients with prostate carcinoma have alterations in serum IGFP levels related to the production of IGFBPs by their tumors, we performed Western ligand blots (WLB) and IGFBP-2 RIA on serum samples from 32 patients with prostate carcinoma of various degrees of clinical severity and compared them to results in 16 healthy age-matched controls. We have also measured serum IGF-I and -II by RIA. The mean level of IGFBP-2 in the prostate cancer patients was 170% of control levels by WLB analysis and 195% of control levels by RIA (P < 0.01). The degree of elevation of IGFBP-2 was related to the stage of the tumor and the levels of the serum tumor marker, prostate-specific antigen. Serum IGFBP-3 levels determined by WLB and serum IGF-I and IGF-II levels measured by RIA after acid chromatography were not different among the subjects with cancer and the normal controls. We conclude that IGFBP-2, which is the main IGFBP produced by prostate epithelial cells, is elevated in the serum of patients with prostate carcinoma, and that the degree of this elevation is related to serum prostate-specific antigen levels and the stage of the tumor. We speculate that prostate-derived IGFBPs may be secreted by prostate tumors and could e of value in understanding the pathophysiology of prostatic tumor growth as well as provide potential diagnostic markers.